chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 15.0
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event, Product storage error
Clinical narrative: This vaccine was given after BUD.  Parent did not report any adverse reaction after receiving this vaccine.
Age: 12.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Product storage error
Clinical narrative: This vaccine was given after BUD.  Parent did not report any adverse reaction after receiving this vaccine.
Age: 18.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: This vaccine was used after BUD. Parent did not report any  adverse reaction  after receiving  this vaccine.
Age: 11.0
Sex: M
Vaccine: UNK
Symptoms: Expired product administered
Clinical narrative: This vaccine was used after BUD. Parent did not report any adverse reaction after receiving this vaccine.
Age: 12.0
Sex: F
Vaccine: MENB
Symptoms: Wrong product administered
Clinical narrative: MenB vaccine by mistake
Age: 55.0
Sex: M
Vaccine: VARZOS
Symptoms: Headache
Clinical narrative: Constant headache since receiving the Shingrix vaccine #1
Age: 71.0
Sex: M
Vaccine: RSV
Symptoms: Body temperature fluctuation, Chills
Clinical narrative: 26 hours after administration of RSV AREXVY by GlaxoSmithKline I developed severe shivering and core temperature drop and then rise. The episode resolved 3 hours later with no futher problems. I bundled up, used a heating pad, drank hot chocolate to get the shivering to stop. I have not had this condition previously. There was no environmental condition that contributed to this episode.
Age: 41.0
Sex: F
Vaccine: HPV9, HPV9
Symptoms: Exposure during pregnancy, Ultrasound scan
Clinical narrative: HCP called to report an AE for GARDASIL 9.  Caller states the patient received GARDASIL 9 on  7/13/2023 and is pregnant and expecting to deliver on  08/17/2023.; No additional AE; This spontaneous report was received from an other health professional referring to a 41-year-old pregnant female patient. The patient is expecting to deliver on 17-AUG-2023 (date of last menstrual period (LMP) was 10-NOV-2022; pregnancy outcome was outcome pending; number of fetus was 1; fetus outcome was unknown).  The patient's pertinent medical history included attention deficit hyperactivity disorder (ADHD), and postpartum depression. Concomitant medications included prochlorperazine maleate (COMPAZINE), promethazine (PHENERGAN) and althaea officinalis (+) ascorbic acid (+) betacarotene (+) biotin (+) calcium carbonate (+) calcium citrate (+) calcium pantothenate (+) choline bitartrate (+) chromium nicotinate (+) colecalciferol (+) copper (+) ferrous bisglycinate (+) iodine (+) levomefolic acid (+) magnesium aspartate (+) manganese citrate (+) mecobalamin (+) molybdenum glycinate (+) nicotinamide (+) phytomenadione (+) prunus spp. (+) spirulina spp. (+) pyridoxine hydrochloride (+) riboflavin (+) selenium (+) thiamine mononitrate (+) tocopherol (+) zinc bis glycinate chelate (+) zingiber officinale rhizome (MULTI COMPLETE PRENATAL VITAMINS). The patient's drug reactions or allergies was reported as no known drug allergy (NKDA). The patient's concurrent conditions were not reported.   On 13-JUL-2023, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, once, administered intramuscularly for prophylaxis (strength, dose, lot #, and expiry date were not provided) (Vaccine exposure during pregnancy). It was reported that treatment was given for the adverse event, but no more information was provided. Routine ultrasounds were performed but no result was reported. The patient had sought for medical attention. No additional adverse events or PQC was reported.
Age: 41.0
Sex: F
Vaccine: HPV9, HPV9
Symptoms: Apgar score normal, Foetal exposure during pregnancy, Small for dates baby
Clinical narrative: HCP called to report an AE for GARDASIL 9.  Caller states the patient received GARDASIL 9 on  7/13/2023 and is pregnant and expecting to deliver on  08/17/2023.; No additional AE; This spontaneous report was received from an other health professional referring to a 41-year-old pregnant female patient. The patient is expecting to deliver on 17-AUG-2023 (date of last menstrual period (LMP) was 10-NOV-2022; pregnancy outcome was outcome pending; number of fetus was 1; fetus outcome was unknown).  The patient's pertinent medical history included attention deficit hyperactivity disorder (ADHD), and postpartum depression. Concomitant medications included prochlorperazine maleate (COMPAZINE), promethazine (PHENERGAN) and althaea officinalis (+) ascorbic acid (+) betacarotene (+) biotin (+) calcium carbonate (+) calcium citrate (+) calcium pantothenate (+) choline bitartrate (+) chromium nicotinate (+) colecalciferol (+) copper (+) ferrous bisglycinate (+) iodine (+) levomefolic acid (+) magnesium aspartate (+) manganese citrate (+) mecobalamin (+) molybdenum glycinate (+) nicotinamide (+) phytomenadione (+) prunus spp. (+) spirulina spp. (+) pyridoxine hydrochloride (+) riboflavin (+) selenium (+) thiamine mononitrate (+) tocopherol (+) zinc bis glycinate chelate (+) zingiber officinale rhizome (MULTI COMPLETE PRENATAL VITAMINS). The patient's drug reactions or allergies was reported as no known drug allergy (NKDA). The patient's concurrent conditions were not reported.   On 13-JUL-2023, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, once, administered intramuscularly for prophylaxis (strength, dose, lot #, and expiry date were not provided) (Vaccine exposure during pregnancy). It was reported that treatment was given for the adverse event, but no more information was provided. Routine ultrasounds were performed but no result was reported. The patient had sought for medical attention. No additional adverse events or PQC was reported.
Sex: U
Vaccine: RV5
Symptoms: Product storage error
Clinical narrative: administration of improperly stored ROTATEQ; This spontaneous report was received from an unspecified reported (Other) and refers to a specific patient of unknown age and gender.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 17-JUL-2023, the patient was vaccinated with improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, dose 2 milliliter, lot #1968392, expiration date: 24-MAY-2024, administered orally for prophylaxis (strength was not provided) (Product storage error).   Temperature excursions were reported as follow: 20-JUN-2023: 34.9 Fahrenheit (F) for 6 hours 34 minutes 0 seconds 03-JUL-2023: 51.4 F for 7 hours 33 minutes 0 seconds 04-JUL-2023: 51.1 F for 24 hours 0 minutes 0 seconds 05-JUL-2023: 50.7 F for 9 hours 27 minutes 0 seconds Time frame: 34.9 F for 6 hours 34 minutes 0 seconds; 51.4 F for 7 hours 33 minutes 0 seconds; 51.1F for 24 hours 0 minutes 0 seconds; 50.7F for 9 hours 27 minutes 0 seconds. There was no previous temperature excursion.  This is one of multiple reports received from the same reporter.; Sender's Comments:  US-009507513-2307USA009292:mother case US-009507513-2307USA009885:
Sex: U
Vaccine: RV5
Symptoms: Product storage error
Clinical narrative: administration of improperly stored ROTATEQ; This spontaneous report was received from a office manager and referred to a patient of unspecified age and gender. The patient's pertinent medical history, current conditions, previous drug reactions or allergies, and concomitant medications were not reported.  On 22-JUN-2023, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) oral liquid, at a dosage of 2 ml administered orally (strength, vaccination scheme frequency, and dose number were not reported; lot number 1968385 with an expiration date reported and established as 22-MAY-2024) (product storage error) for prophylaxis.  It was stated that the suspect vaccine had the following temperature excursions: 34.9 degree Fahrenheit (F) with a time frame of 6 hours and 34 minutes on 20-JUN-2023. There was no previous temperature excursion reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2307USA009885:
Sex: U
Vaccine: RV5
Symptoms: Product storage error
Clinical narrative: administration of improperly stored ROTATEQ; This spontaneous report was received from customer and refers to a patient of unknown age and gender. No information was provided regarding the patient's concurrent conditions, concomitant medications, or relevant medical history.  On 05-JUL-2023, the patient was vaccinated with a dose of improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 2 milliliter, lot #1968385, expiration date: 22-MAY-2024, administered orally for prophylaxis (improper storage of product in use). Temperature excursion details: 34.9 degree Fahrenheit for 6 hours 34 minutes (20-JUN-2023); 51.4 degree Fahrenheit for 7 hours 33 minutes (03-JUL-2023); 51.1 degree Fahrenheit for 24 hours (04-JUL-2023); 50.7 degree Fahrenheit for 9 hours 27 minutes (05-JUL-2023). There was no previous temperature excursions reported.  This is one of several cases received from the same reporter (cross-referenced with US-009507513-2307USA009292).; Sender's Comments:  US-009507513-2307USA009292:mother case
Sex: U
Vaccine: RV5
Symptoms: Product storage error
Clinical narrative: improperly stored administered ROTATEQ that was not supported/7/14/2023 1968385 5/22/2024; This spontaneous report was received from customer and refers to a patient of unknown age and gender. No information was provided regarding the patient's concurrent conditions, concomitant medications, or relevant medical history.  On 14-JUL-2023, the patient was vaccinated with a dose of improperly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 2 milliliter, lot #1968385, expiration date: 22-MAY-2024, administered orally for prophylaxis (improper storage of product in use). Temperature excursion details: 34.9 degree Fahrenheit for 6 hours 34 minutes (20-JUN-2023); 51.4 degree Fahrenheit for 7 hours 33 minutes (03-JUL-2023); 51.1 degree Fahrenheit for 24 hours (04-JUL-2023); 50.7 degree Fahrenheit for 9 hours 27 minutes (05-JUL-2023). There was no previous temperature excursions reported.  This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-2307USA009885:
Sex: U
Vaccine: RV5
Symptoms: Product storage error
Clinical narrative: She also provided names and administration dates of improperly stored administered ROTATEQ that was not supported 7/10/2023 1968385 5/22/2024; This spontaneous report was received from an unspecified reporter and refers to a patient of unknown age and gender. No information on patient's medical history, current conditions and concomitant medications was provided.      On 10-JUL-2023, the patient was vaccinated with improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # 1968385 and expiration date 22-MAY-2024, 2 milliliters for prophylaxis (dose number and route of administration were not provided) (product storage error). Temperature excursion was 34.9 degrees Fahrenheit (F) for 6 hours 34 minutes 0 seconds; 51.4 F for 7 hours 33 minutes 0 seconds; 51.1F for 24 hours 0 minutes 0 seconds; 50.7F for 9 hours 27 minutes 0 seconds. No previous excursion was provided.; Sender's Comments:  US-009507513-2307USA009885:
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No symptoms reported. No additional AE; improperly stored administered PROQUAD; This spontaneous report has been received from a nurse concerning a 4-year-old patient of unknown gender.  The patient's concurrent conditions, medical history, concomitant therapies and drug/allergy history were not reported.  On 03-JUL-2023, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(rHA) (PROQUAD), 0.5 milliliters (ml), lot # W024551 (has been verified to be a valid lot number, expiration date reported and upon internal validation established as 31-JAN-2024) for prophylaxis (anatomical location and route of administration were not reported). The vaccine was stored at a temperature of 0.6 Celsius degrees (C) (-10C up to 8 C) for 6 hours, 15 minutes and 0 seconds. The vaccine did not suffer previous temperature excursions (Product storage error). No additional adverse event reported.; Sender's Comments:  US-009507513-2308USA001106:
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: HBP called to report a T/E on PROQUAD that was improperly stored and administered. Confirmed no symptoms or side effects reported. See related AE cases 02441564 and 02441564. No additional AE/no PQC.         ?    Names of vaccines involved (includi; HBP called to report a T/E on PROQUAD that was improperly stored and administered. Confirmed no symptoms or side effects reported. See related AE cases 02441564 and 02441564. No additional AE/no PQC.         ?    Names of vaccines involved (includi; This spontaneous report was received from an administrator and referred to a 4-year-old patient of unknown gender.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant medications included sterile diluent.   On an unknown date, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous injection, 0.5 milliliter, once (lot #X007085 has been verified to be a valid lot number, expiration date: 04-SEP-2024), administered for prophylaxis (strength, and route of administration were not provided).  01-AUG-2023, the reporter reported a temperature excursion (temperature: 17.8F for 1 hour 30minutes) for the vaccine that was improperly stored and administered (product storage error). Confirmed no symptoms or side effects reported. No additional adverse event or product quality complaint reported (no adverse event).
Sex: U
Vaccine: PNC15
Symptoms: Product storage error
Clinical narrative: No additional AE; patient was administered VAXNEUVANCE after it experienced a supported temperature excursion; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender.   The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 09-AUG-2023, the patient was vaccinated with improperly stored dose (Product storage error) of pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection, pre-filled syringe, 0.5 ml, lot # reported and confirmed as: X004289, expiration date reported and confirmed as: 10-DEC-2024 (site and route of administration were not provided) for prophylaxis. Temperature excursion information: 11.2 degree Celsius for 2 hours 36 minutes; no previous temperature excursion. There were no side effects reported.   This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2308USA004183:02447220 US-009507513-2308USA003975:02447218 US-009507513-2308USA004087:02447221
Age: 0.58
Sex: M
Vaccine: PNC15, RV5
Symptoms: Product storage error
Clinical narrative: No additional AE; patient was administered VAXNEUVANCE and ROTATEQ after they experienced a supported temperature excursion; This spontaneous report was received from a medical assistant and refers to a 7-month-old male patient  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 09-AUG-2023, the patient was vaccinated with improperly stored doses (Product storage error) of pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection, pre-filled syringe, 0.5 ml, lot # reported and confirmed as: X004289, expiration date reported and confirmed as: 10-DEC-2024 (site and route of administration were not provided); and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 2 ml, lot # reported and confirmed as: W036404, expiration date reported and confirmed as: 24-APR-2024, administered orally. Both vaccines were administered for prophylaxis. Temperature excursion information: 11.2 degree Celsius for 2 hours 36 minutes; no previous temperature excursion. There were no side effects reported.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2308USA003962:02447222 US-009507513-2308USA004183:02447220 US-009507513-2308USA004087:02447221
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs; Caller reported vaccine administered after temperature excursions.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 04-AUG-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5 milliliter, lot #X006983, expiration date: 07-MAR-2025, administered intramuscularly for prophylaxis (strength was not provided). This vaccine underwent temperature excursion before adminisration in 18.3 degree Farenheit (F) for 1 hour 5 minutes. No aditional adverse events were reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs; Caller reported vaccine administered after temperature excursions.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 08-AUG-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5 milliliter, lot #X006983, expiration date: 07-MAR-2025, administered intramuscularly for prophylaxis (strength was not provided). This vaccine underwent temperature excursion before administration in 18.3 degree Farenheit (F) for 1 hour and 5 minutes. No additional adverse events were reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs; Caller reported vaccine administered after temperature excursions.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 28-JUL-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5 milliliter, lot #W039293, expiration date: 11-DEC-2024, administered intramuscularly for prophylaxis (strength was not provided). This vaccine underwent temperature excursion before administration in 18.3 degree Farenheit (F) for 1 hour 5 minutes. No additional adverse events were reported.
Sex: U
Vaccine: HIBV
Symptoms: Expired product administered, No adverse event
Clinical narrative: No side effects reported.; HCP calling to report an expired dose of PEDVAX HIB was given to a patient. No side effects reported. HCP reports the vaccine has not had any temperature excursions. No additional information provided. Additional AE case filed, refer to case #0244910; This spontaneous report was received from Other Health Professional and refers to a 3-year-old patient of unknown gender.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 03-AUG-2023, the patient started therapy with haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) intramuscular injection, 0.5 ml, lot #T037651, expiration date: 20-JUL-2023, administered for prophylaxis (strength, and route of administration were not provided).  On 03-AUG-2023, HCP called to report an expired dose of PEDVAX HIB was given to a patient. No side effects reported. HCP reports the vaccine has not had any temperature excursions.No additional information provided. Additional AE case filed, refer to case #0244910. No PQC.
Sex: U
Vaccine: MMR
Symptoms: Expired product administered
Clinical narrative: No other AE and no PQC; HBP calling to report an administration of an expired dose of MMR II was administered to a patient on 08/10/2023; This spontaneous report has been received from a "HBP" concerning a patient of unknown age and gender.  The patient's concurrent conditions, medical history, concomitant therapies and drug/allergy history were not reported.  On 10-AUG-2023, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II), lot # U022175 (has been verified to be a valid lot number, expiration date reported and upon internal validation established as 14-JUL-2023) for prophylaxis (dose, anatomical location, and route of administration were not reported) (expired product administered). No symptoms or adverse events were reported.
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AEs; vaccine administered after temperature excursions; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medication were not provided.  On 08-AUG-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin (rHA)) (PROQUAD) injection (0.5ml, lot #X011979, expiration date: 18-JUL-2024; strength was not provided) intramuscularly for prophylaxis. It was reported the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin (rHA)) (PROQUAD) was administered after temperature excursions of 18.3-degree Fahrenheit for a time frame of 1 hour and 5 minutes. There was no previous temperature excursion. No additional information was provided. No additional adverse events (AEs) or product quality complaint (PQC) were reported.
Sex: M
Vaccine: VARZOS
Symptoms: Pulmonary embolism, Pulmonary thrombosis, Ultrasound scan abnormal
Clinical narrative: I experienced a pulmonary embolism about four weeks after getting the injection I've been doing tests and they found nothing wrong with me so it was definitely the injection that cost me to have a Clo; blood clot in my lungs; Sweating; Passed out; almost died; This serious case was reported by a consumer and described the occurrence of pulmonary embolism in a 55-year-old male patient who received Herpes zoster (Zoster vaccine) for prophylaxis.   Concomitant products included apixaban (Eliquis).   On 06-DEC-2022, the patient received the 2nd dose of Zoster vaccine. On 31-DEC-2022, 25 days after receiving Zoster vaccine, the patient experienced pulmonary embolism (Verbatim: I experienced a pulmonary embolism about four weeks after getting the injection I've been doing tests and they found nothing wrong with me so it was definitely the injection that cost me to have a Clo) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), pulmonary thrombosis (Verbatim: blood clot in my lungs) (serious criteria hospitalization and GSK medically significant), sweating (Verbatim: Sweating) (serious criteria hospitalization), passed out (Verbatim: Passed out) (serious criteria hospitalization and GSK medically significant) and near death experience (Verbatim: almost died) (serious criteria hospitalization and GSK medically significant). The outcome of the pulmonary embolism and passed out were resolved and the outcome of the pulmonary thrombosis, sweating and near death experience were not reported.   The reporter considered the pulmonary embolism and pulmonary thrombosis to be related to Zoster vaccine. It was unknown if the reporter considered the sweating, passed out and near death experience to be related to Zoster vaccine.     The company considered the pulmonary embolism and pulmonary thrombosis to be related to Zoster vaccine. It was unknown if the company considered the sweating, passed out and near death experience to be related to Zoster vaccine.   Additional Information: GSK Receipt date: 09-AUG-2023 The reporter reported about himself, he passed out and he came to all his vitals were fine. Just sweating profusely took him to the hospital could not from that out of you. Nothing was wrong with him. Then he needed to get some kind of answer after CAT (Computerised tomogram) scans ultrasound they found that he had a blood clot in his lungs, so he had a pulmonary embolism.  He experienced a pulmonary embolism about four weeks after getting the injection he had been doing tests and they found nothing wrong with him, so it was definitely the injection that cost him. it was December 31 of 2022 that this took place he almost died he had gone through months and months of testing.  They found nothing wrong with him that caused him to get this clot.  The only conclusion was he had the injection done the beginning of December and now because they could not get a determined answer, he had to be on the rest of his life. The reporter consented to follow up.
Sex: F
Vaccine: VARZOS
Symptoms: Atrial fibrillation, Fear of disease, Supraventricular tachycardia
Clinical narrative: prone to SVT and the A-Fib reaction; prone to SVT and the A-Fib reaction; This serious case was reported by a consumer and described the occurrence of atrial fibrillation in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 09-MAY-2023, the patient received the 1st dose of Shingrix. On 30-MAY-2023, 21 days after receiving Shingrix, the patient experienced atrial fibrillation (Verbatim: prone to SVT and the A-Fib reaction) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required). On an unknown date, the patient experienced supraventricular tachycardia (Verbatim: prone to SVT and the A-Fib reaction) (serious criteria hospitalization). The outcome of the atrial fibrillation was not resolved and the outcome of the supraventricular tachycardia was not reported.   It was unknown if the reporter considered the atrial fibrillation and supraventricular tachycardia to be related to Shingrix.     It was unknown if the company considered the atrial fibrillation and supraventricular tachycardia to be related to Shingrix.   Additional Information: GSK Receipt Date: 10-AUG-2023 The patient self-reported this case. The patient was prone to supraventricular tachycardia and the atrial fibrillation. She had these reactions for first time. She was very reluctant to get the second dose of Shingrix due to the fear of atrial fibrillation. Reporter consented to follow up.
Sex: M
Vaccine: VARZOS
Symptoms: Atrial fibrillation, Condition aggravated, Dizziness
Clinical narrative: dizziness; Atrial fibrillation; This serious case was reported by a consumer and described the occurrence of atrial fibrillation in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included atrial fibrillation (long history of atrial fibrillation, after stent placement in multiple vessels in Oct 2022 the atrial fibrillation ceased). Concurrent medical conditions included heart disease, unspecified, stroke, diabetes, spinal stenosis, intervertebral disc disorder, vascular disorder and post-traumatic stress disorder. Concomitant products included apixaban (Eliquis), metoprolol, clopidogrel bisulfate (Plavix), glipizide, tramadol, atorvastatin calcium (Lipitor) and prazosin hydrochloride (Minipress).   On 02-MAY-2023, the patient received the 2nd dose of Shingrix. On 09-AUG-2023, 99 days after receiving Shingrix, the patient experienced atrial fibrillation (Verbatim: Atrial fibrillation) (serious criteria GSK medically significant). On an unknown date, the patient experienced dizziness (Verbatim: dizziness). The outcome of the atrial fibrillation was not resolved and the outcome of the dizziness was unknown.   It was unknown if the reporter considered the atrial fibrillation and dizziness to be related to Shingrix.     It was unknown if the company considered the atrial fibrillation and dizziness to be related to Shingrix.   Additional Information: GSK receipt date: 13-Aug-2023 This report was submitted via the online direct entry reporting system. After second shot of Shingrix atrial fibrillation returned with dizziness.  The atrial fibrillation symptoms were not treated. The reporter consented to follow-up.
Sex: U
Vaccine: VARZOS
Symptoms: Post herpetic neuralgia, Vaccination failure
Clinical narrative: developed PHN symptoms / Suspected vaccination failure; developed PHN symptoms; This serious case was reported by a nurse via sales rep and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: developed PHN symptoms / Suspected vaccination failure) (serious criteria GSK medically significant) and post herpetic neuralgia (Verbatim: developed PHN symptoms). The outcome of the vaccination failure was unknown and the outcome of the post herpetic neuralgia was not reported.   It was unknown if the reporter considered the vaccination failure and post herpetic neuralgia to be related to Shingrix.     It was unknown if the company considered the vaccination failure and post herpetic neuralgia to be related to Shingrix.   Additional Information: GSK Receipt date: 10-AUG-2023 A reporter reported that patient developed PHN (post herpetic neuralgia) symptoms even after having been vaccinated. This case was considered as suspected vaccination failure since the details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of post herpetic neuralgia were unknown at the time of reporting. The reporter did not agree to follow up from GSK.
Age: 13.0
Sex: M
Vaccine: MENB
Symptoms: Wrong product administered
Clinical narrative: Bexsero was given to 13 year old patient who was supposed to be given HPV vaccine; This non-serious case was reported by a nurse and described the occurrence of wrong vaccine administered in a 13-year-old male patient who received Men B NVS (Bexsero) for prophylaxis.   On 08-AUG-2023, the patient received Bexsero. On 08-AUG-2023, an unknown time after receiving Bexsero, the patient experienced wrong vaccine administered (Verbatim: Bexsero was given to 13 year old patient who was supposed to be given HPV vaccine). The outcome of the wrong vaccine administered was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 09-AUG-2023 Nurse reported to supervisor and supervisor was seeking information on what to do if Bexsero was given at younger age than recommended. The patient received Bexsero instead of HPV vaccine, which led to wrong vaccine administered. The reporter consented to follow up.
Sex: U
Vaccine: MMR
Symptoms: Intercepted product storage error, Product storage error
Clinical narrative: received the product frozen when it was delivered to the clinic, and put it into the freezer; This non-serious case was reported by a nurse via sales rep and described the occurrence of intercepted product storage error in a patient who received MMR (Priorix) (batch number GXZ79, expiry date 2024) for prophylaxis.   On an unknown date, the patient did not receive Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced intercepted product storage error (Verbatim: received the product frozen when it was delivered to the clinic, and put it into the freezer). The outcome of the intercepted product storage error was unknown.   This report is made without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: Receipt date: 10-Aug-2023 The nurse reported that Priorix was not used on any patients in this case report.  The reporter received the product frozen when it was delivered to the clinic, and put into the freezer, where it had remained the past 2 weeks. The reporter had marked the vaccine 'do not use after they spoke on the day of reporting, and placed it into the refrigerator, while planning a follow up tomorrow, who would also send a medical information letter, she requested on storage outside of temperature values and would discuss this situation directly.  The reporter would following up with the logistics department at this base tomorrow (already emailed and left VM this afternoon) to ensure another communication on storage of this vaccine. The 20 doses of Priorix had storage temperature excursion, which led to intercepted product storage error.
Age: 12.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: This vaccine was given after BUD. Parent  did not report any adverse reaction after  vaccine was received.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Axillary pain, Pain, Pain in extremity
Clinical narrative: When I got the shot I had some expected local pain which seemed to widen in area over the next day or so to include my arm pit area.  After a couple days the area shrank in size and is now just in the front of the arm joint.  From the time the pain shrank in area it has remained to this day. I have a sharp burning pain in the shoulder joint area.
Age: 19.0
Sex: M
Vaccine: UNK
Symptoms: Expired product administered, No adverse event
Clinical narrative: This vaccine was used after BUD.  Parent did not report any  adverse vaccine reaction after it was received.
Age: 19.0
Sex: M
Vaccine: UNK
Symptoms: Expired product administered, No adverse event
Clinical narrative: This vaccine was given after BUD. Parent did not report any adverse reaction after vaccine.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infection
Age: 32.0
Sex: F
Vaccine: COVID19-2, FLUC4
Symptoms: Guillain-Barre syndrome, Lumbar puncture abnormal, Magnetic resonance imaging abnormal
Clinical narrative: Guillain-Barre Syndrome
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infection
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19 pneumonia, SARS-CoV-2 test positive
Clinical narrative: Patient admitted with COVID pneumonia on 8/13/23
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Facial paresis, Ischaemic stroke
Clinical narrative: ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY LEFT FACIAL MUSCLE WEAKNESS
Age: 11.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: 11 year old patient was given 12 year old + COVID dose
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Epilepsy
Clinical narrative: EPILEPSY, INTRACTABLE
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Embolic stroke, Symptom recurrence
Clinical narrative: ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY 1/31/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome, Sleep apnoea syndrome
Clinical narrative: SLEEP APNEA OBSTRUCTIVE SLEEP APNEA
Age: 97.0
Sex: F
Vaccine: COVID19
Symptoms: Angina pectoris
Clinical narrative: STABLE ANGINA
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Carotid artery stenosis, Neuropathy peripheral
Clinical narrative: PERIPHERAL NEUROPATHY 4/1/2023 LEFT CAROTID ARTERY STENOSIS
Age: 1.0
Sex: F
Vaccine: DTAP, HIBV, IPV, MMR
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse effects at this time. ActHib given was expired by 3 days.
Age: 65.0
Sex: M
Vaccine: RSV
Symptoms: Arthralgia, Fatigue
Clinical narrative: Developed painful joint pain in fingers, ribs and feet on Day 2 and feeling very tired
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary embolism
Clinical narrative: SADDLE PULMONARY EMBOLISM 4/26/2023 ACUTE PULMONARY EMBOLISM  ACUTE PULMONARY EMBOLISM 4/27/2023 ACUTE PULMONARY EMBOLISM
Age: 0.17
Sex: M
Vaccine: PPV
Symptoms: No adverse event, Product administered to patient of inappropriate age
Clinical narrative: Error of administration, a PPV23 vaccine was administered to a 2 months old patient.  No adverse event was observed or reported.
Age: 93.0
Sex: F
Vaccine: COVID19
Symptoms: Facial paresis, Nasopharyngeal tumour
Clinical narrative: R29.810 LEFT FACIAL MUSCLE WEAKNESS 12/30/2022 NASOPHARYNGEAL MASS
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Ischaemic stroke, Vena cava filter insertion
Clinical narrative: I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 4/23/2023 PRESENCE OF INFERIOR VENA CAVA FILTER
Age: 62.0
Sex: M
Vaccine: PNC20
Symptoms: Erythema, Hypersensitivity, Pruritus, Urticaria
Clinical narrative: Erythema, pruritus, welts/wheals likely secondary to an allergic reaction. Educated patient that this is self-limiting illness that requires conservative management. Avoid triggers and irritants. Tepid, and colloidal oatmeal baths to help with pruritus. H2 blocker and prednisone started. Take benadryl as needed. May benefit from OTC allergy medication (Claritin, Zyrtec). Hydrocortisone cream PRN for pruritus and erythema. Emollients (Eucerin, aquaphor) PRN for eruptions. Calamine lotion PRN for pruritus. Can use a moisture barrier PRN (zinc oxide). If any tongue swelling, shortness of breath, fever, or feeling like throat is closing go to nearest ER. If rash is not getting better please notify pcp. f/u with PCP in 2-3 days for lack of improvement or sooner for worsening s/s
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Anaemia, Angina unstable
Clinical narrative: I20.0 UNSTABLE ANGINA 4/25/2023 ANEMIA UNSTABLE ANGINA I21.4 ACUTE NON ST ELEVATION MI 4/25/2023 ANEMIA UNSTABLE ANGINA
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect route of product administration
Clinical narrative: Left shoulder at bone. They didn't put it on the muscle part.    Hospital was not admitted
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: ACUTE DVT OF LEFT LEG, UNSPECIFIED VEIN
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infection.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: ACUTE DVT OF RIGHT FEMORAL VEIN ACUTE DVT OF LEFT FEMORAL VEIN
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Angioedema
Clinical narrative: ANGIOEDEMA, INIT ANGIOEDEMA, SUBSEQ
Age: 7.0
Sex: F
Vaccine: DTAP
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Child was given DTaP instead of Tdap by mistake. Per package insert, the indication for DTaP is aged 6 weeks through 6 years, prior to 7th birthday, and this child was 7 years and 1 month old.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA
Age: 7.0
Sex: F
Vaccine: HPV9, MNQ
Symptoms: Arthralgia, Hypoaesthesia, Injection site erythema, Injection site swelling, Pain in extremity
Clinical narrative: Pt. experienced pain in R. shoulder and arm starting on 8/11/23.  Reports having spots on R. hand with intermittent numbness of R. hand starting on 8/11/23. Injection site red, raised and size of a silver dollar.  With no improvement pt went to ER on 8/14/23.  Monitored and released same day.  Was told may have hit a nerve during administration of vaccine , use ice intermittently x 1 week and see a provider if no improvements.  On 8/16/23, Mother reports pain improving, redness and swelling now size of nickle , still having intermittent numbness of R. hand.  Mother will call back if no improvements or sx's worsen.  RN
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE ST ELEVATION MI, LATERAL WALL
Age: 0.33
Sex: F
Vaccine: HIBV, PNC15, RV5, TDAP
Symptoms: Immunisation, Product administered to patient of inappropriate age, Pyrexia, Wrong product administered
Clinical narrative: Tdap given to an infant on 07/14/2023.   Tdap is indicated for ages 7 and above.  The patient was not in the age range indicated for Tdap.   Patient should've gotten pediarix.  I called parent.  Child had a fever and no other symptom.  Mother came in with child to be revaccinated with the correct vaccine (Pediarix) on 08/11/2023.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA ACUTE NON ST ELEVATION MI
Age: 0.5
Sex: F
Vaccine: COVID19-2, DTAPIPVHIB, PNC13, RV5
Symptoms: Underdose
Clinical narrative: Received lower than recommended dose of moderna bivalent vaccine. Patient should have received 25 mcg, but instead received 10 mcg.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic respiratory failure, Obstructive sleep apnoea syndrome, Respiratory failure
Clinical narrative: OBSTRUCTIVE SLEEP APNEA CHRONIC HYPOXEMIC RESPIRATORY FAILURE
Age: 43.0
Sex: F
Vaccine: COVID19-2
Symptoms: Idiopathic urticaria, Rash
Clinical narrative: Please note, I was counseling pt on a separate medication, but she mentioned to me that she had a "Covid booster" and that sometime after her booster she developed a rash. She described it as "not hives," but a skin condition. I don't know when she had the booster or which manufacturer it was. I don't know when her symptoms started, but she seemed to indicate soon after. She said she doesn't know if this skin condition was a result of the vaccination or not. She has been treated with Xolair though due to diagnosis of idiopathic urticaria. I also did not advise pt I was going to report this AE as I wasn't aware at the time this was something we are obligated to do at my workplace (even if we didn't administer the vaccine)
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient vaccinated against and then tested positive for COVID-19
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Myocarditis
Clinical narrative: MYOCARDITIS
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: NEUROPATHY
Age: 1.0
Sex: M
Vaccine: MMRV, VARCEL
Symptoms: Wrong product administered
Clinical narrative: MMR and Varivax were ordered and I administered Proquad and Varivax
Age: 29.0
Sex: F
Vaccine: TDAP
Symptoms: Arthralgia
Clinical narrative: Patient reported pain in left shoulder following administration
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: ACUTE DVT OF LEFT LEG, UNSPECIFIED VEIN ACUTE DVT OF LEFT TIBIAL VEIN
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Coagulopathy
Clinical narrative: COAGULOPATHY, UNSPECIFIED TYPE
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Respiratory failure
Clinical narrative: HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPOXIA
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Aortic dissection, Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA 3/28/2023 DISSECTION OF THORACOABDOMINAL AORTA
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome, Prostate cancer
Clinical narrative: G47.33 ADULT OBSTRUCTIVE SLEEP APNEA 4/26/2023 PROSTATE CANCER
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA, MODERATE HYPOXIA
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Lung adenocarcinoma, Respiratory failure
Clinical narrative: ACUTE HYPERCAPNIC RESPIRATORY FAILURE 4/2/2023 ADENOCARCINOMA LUNG, UNSPECIFIED SITE CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/2/2023 ADENOCARCINOMA LUNG, UNSPECIFIED SITE
Age: 0.5
Sex: M
Vaccine: COVID19-2, DTAPIPVHIB, PNC13, RV5
Symptoms: Underdose
Clinical narrative: Received lower than recommended dose of moderna bivalent vaccine. Patient should have received 25 mcg, but instead received 10 mcg.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Anaemia, Aortic arteriosclerosis, Dyspnoea, Respiratory failure
Clinical narrative: J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/11/2023 HX OF ESOPHAGEAL CANCER J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/24/2023 HX OF ESOPHAGEAL CANCER J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/11/2023 ATHEROSCLEROSIS OF AORTA J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/24/2023 ATHEROSCLEROSIS OF AORTA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/11/2023 ANEMIA J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/24/2023 ANEMIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 4/11/2023 SHORTNESS OF BREATH J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/24/2023 SHORTNESS OF BREATH
Age: 3.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, No adverse event, Product preparation error
Clinical narrative: Patient was given full vial 1.2 ML of undiluted 6 mos-4 yrs. No Adverse even was noted at the time given. Mom was contacted later on that evening and again the next morning and Mom reported patient was doing fine.
Age: 41.0
Sex: F
Vaccine: HEP
Symptoms: Fatigue, Headache, Oropharyngeal pain, Pyrexia
Clinical narrative: HEADACHE, FEVER, FATIGUE, SORE THROAT TYLENOL WAS GIVEN TO HELP RELIEVE SYMPTOMS THIS MORNING 08/16/2023. TEMPERATURE IS DOWN AND HEADACHE HAS RESOLVED. EMPLOYEE STATED SHE STILL FEELS REALLY FATIGUED AND THROAT CONTINUES TO BE SORE.
Age: 4.0
Sex: F
Vaccine: COVID19-2, MMR, PNC13
Symptoms: Underdose
Clinical narrative: Received lower than recommended dose of moderna bivalent vaccine. Patient should have received 25 mcg, but instead received 10 mcg.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Reversible ischaemic neurological deficit
Clinical narrative: REVERSIBLE ISCHEMIC NEUROLOGIC DEFICIT SYNDROME
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Lacunar stroke, Transient ischaemic attack
Clinical narrative: TRANSIENT CEREBRAL ISCHEMIA ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Discontinued product administered, No adverse event
Clinical narrative: None.Dose of pfizer monovalent administered on 04/20/2023 after authorization was cancelled on 04/18/2023.Patient contacted,Denies any adverse event.Revaccination reccomended.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Epilepsy
Clinical narrative: EPILEPSY, UNSPECIFIED
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Hypoxia, Pulmonary embolism
Clinical narrative: ACUTE PULMONARY EMBOLISM 4/9/2023 DYSPNEA HYPOXIA 4/9/2023 DYSPNEA
Age: 12.0
Sex: F
Vaccine: MENB
Symptoms: Wrong product administered
Clinical narrative: Menquadfi ordered- nurse administered wrong vaccine due to verbal order- Bexsero meningococcal vaccine administered instead. Patient to return 8/21/2023 to receive the correct vaccine of Menquadfi.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: PERIPHERAL NEUROPATHY
Age: 2.0
Sex: F
Vaccine: COVID19-2
Symptoms: Underdose
Clinical narrative: Received lower than recommended dose of moderna bivalent vaccine. Patient should have received 25 mcg, but instead received 10 mcg.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Alcohol use disorder, Alcohol withdrawal syndrome, Hypotension
Clinical narrative: I95.9 HYPOTENSION 3/11/2023 SEVERE ALCOHOL USE DISORDER W ALCOHOL WITHDRAWAL, UNCOMPLICATED
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Subendocardial ischaemia
Clinical narrative: SUBENDOCARDIAL ISCHEMIA HYPOXIA
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Epilepsy, Uterine leiomyoma
Clinical narrative: G40.919 EPILEPSY, INTRACTABLE 3/31/2023 UTERINE FIBROIDS